Plasma cell myeloma refractory
RecruitingPhase 3 Study Comparing JNJ-79635322 with Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma after 1‑3 Prior Treatments
Phase 3 Study Comparing JNJ-79635322 with Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma after 1‑3 Prior Treatments
- Disease:Plasma cell myeloma refractory
- Substances:TeclistamabIGG1 TRISPECIFIC MONOCLONAL ANTIBODY AGAINST T-CELL RECEPTOR CD3, B-CELL MATURATION ANTIGEN AND G PROTEIN-COUPLED RECEPTOR CLASS C GROUP 5 MEMBER D
Spain- Participants:18–64 years · 65+ years
- Substances:Teclistamab
- Sponsor:Janssen Cilag International












